Home » Stocks » NLTX

Neoleukin Therapeutics, Inc. (NLTX)

Stock Price: $12.06 USD 0.06 (0.50%)
Updated December 4, 1:14 PM EST - Market open

NLTX Stock Price Chart

Key Info

Market Cap 505.25M
Revenue (ttm) n/a
Net Income (ttm) -28.74M
Shares Out 54.12M
EPS (ttm) -2.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $12.06
Previous Close $12.00
Change ($) 0.06
Change (%) 0.50%
Day's Open 12.01
Day's Range 11.76 - 12.25
Day's Volume 59,920
52-Week Range 4.06 - 17.05

NLTX Stock News

GlobeNewsWire - 1 week ago

SEATTLE, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo ...

GlobeNewsWire - 3 weeks ago

SEATTLE, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo ...

GlobeNewsWire - 3 weeks ago

- NL-201 enhances activity of checkpoint inhibitors and tumor-targeting antibodies and increases immune cell stimulation -

GlobeNewsWire - 3 weeks ago

- NL-201 IND submission anticipated by year end 2020 -

GlobeNewsWire - 4 weeks ago

- I ntranasal administration of NL-CVX1 protects hamsters from lethal SARS-CoV-2 infection –

GlobeNewsWire - 1 month ago

SEATTLE, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo ...

GlobeNewsWire - 1 month ago

SEATTLE, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo ...

Investopedia - 2 months ago

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.

Other stocks mentioned: AZN, BIIB, MNTA, PRGO, RLMD, SNY, SUPN, TAK
GlobeNewsWire - 2 months ago

SEATTLE, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de no...

Zacks Investment Research - 3 months ago

Neoleukin (NLTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 3 months ago

Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

SEATTLE, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de nov...

GlobeNewsWire - 3 months ago

SEATTLE, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de nov...

GlobeNewsWire - 3 months ago

SEATTLE, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo...

The Motley Fool - 4 months ago

The drug developer has an intriguing technology platform and expects to enter clinical trials before the end of 2020, but there are a few things investors cannot overlook.

The Motley Fool - 4 months ago

Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.

Other stocks mentioned: DRRX, RLMD
Zacks Investment Research - 5 months ago

Neoleukin (NLTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The Motley Fool - 5 months ago

The development-stage drug company announced the pricing of a public offering of common stock.

GlobeNewsWire - 5 months ago

SEATTLE, July 02, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de n...

GlobeNewsWire - 5 months ago

SEATTLE, July 01, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de no...

Zacks Investment Research - 5 months ago

Neoleukin Therapeutics (NLTX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

GlobeNewsWire - 5 months ago

- NL-201 demonstrates durable antitumor activity in animal tumor models - - NL-201 and targeted variants improve outcomes when combined with CAR-T cells in vivo - - Conditional activation of...

Investopedia - 5 months ago

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q3 2020.

Other stocks mentioned: AMPH, CRON
GlobeNewsWire - 6 months ago

SEATTLE, June 01, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de nov...

Zacks Investment Research - 6 months ago

Neoleukin (NLTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Seeking Alpha - 8 months ago

Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

SEATTLE, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de n...

Benzinga - 10 months ago

Here are three stocks that have broken out of above resistance and are looking higher: Neoleukin Therapeutics, Inc.

Other stocks mentioned: SE, XPEL
GlobeNewsWire - 11 months ago

SEATTLE, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de n...

GlobeNewsWire - 11 months ago

SEATTLE, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de n...

GlobeNewsWire - 11 months ago

SEATTLE, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de no...

About NLTX

Neoleukin Therapeutics, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin T... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
2003
Employees
65
Stock Exchange
NASDAQ
Ticker Symbol
NLTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for NLTX stock is "Strong Buy." The 12-month stock price forecast is 22.71, which is an increase of 88.31% from the latest price.

Price Target
$22.71
(88.31% upside)
Analyst Consensus: Strong Buy